Medpace Holdings, Inc.

NasdaqGS:MEDP 주식 리포트

시가총액: US$11.8b

Medpace Holdings 과거 순이익 실적

과거 기준 점검 4/6

Medpace Holdings은 연평균 21.6%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 4.6% 감소했습니다. 매출은 연평균 19%의 비율로 증가했습니다. Medpace Holdings의 자기자본이익률은 76.9%이고 순이익률은 17.2%입니다.

핵심 정보

21.61%

순이익 성장률

25.60%

주당순이익(EPS) 성장률

Life Sciences 산업 성장률21.51%
매출 성장률19.01%
자기자본이익률76.95%
순이익률17.19%
최근 순이익 업데이트31 Mar 2026

최근 과거 실적 업데이트

Recent updates

MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Resilience

Medpace Holdings' analyst price target has been reset from about $582 to roughly $495 as analysts factor in updated assumptions for revenue growth, margins and future P/E multiples, while still pointing to company specific strengths highlighted in recent research coverage and upgrades. Analyst Commentary Street research around Medpace has recently centered on recalibrating price targets while still emphasizing company specific strengths.

Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Apr 26
Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Medpace Holdings: Downgrade To 'Buy' As Revenue Growth Remains, But With Caution Ahead

Apr 24

MEDP: Slower Revenue Assumptions Will Test Rich Multiple And 2026 Execution

Medpace Holdings' analyst-derived fair value has inched up by about $5 to roughly $357, as analysts weigh higher assumed profit margins and a richer future P/E against slower projected revenue growth and a slightly higher discount rate, while incorporating a wave of recent rating upgrades and higher price targets clustered around $419 to $522. Analyst Commentary Recent research on Medpace reflects a mix of upgrades and cautious fine tuning, with several firms lifting ratings while keeping a close eye on valuation, end market trends, and execution risk.

MEDP: Efficient Biotech Contracts And Buybacks Will Support Elevated Market Expectations

Analysts have inched up their blended price target on Medpace Holdings to about $500 per share from roughly $490, citing the company’s efficiency in contract research, ongoing biotech-focused wins, and a series of recent rating upgrades as key reasons for this recalibration. Analyst Commentary Recent research remains broadly constructive on Medpace, with several firms adjusting ratings and price targets as they reassess valuation, execution, and exposure to biotech customers.

MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Strength

Analysts have nudged their overall price expectations for Medpace modestly higher, reflected in a slightly lower discount rate of 7.78% and small upward tweaks to revenue growth and profit margin assumptions. These changes are supported by a series of recent rating upgrades and fresh price targets in the $419 to $660 range.

MEDP: Efficiency And Biotech Exposure Will Support Margin Strength Going Forward

Analysts have lifted their implied fair value estimate for Medpace Holdings to $582 from $510, citing the company's efficiency as a contract research organization, stronger profit margin assumptions at 17.94%, and a higher future P/E of about 29.35x as key supports for the updated price targets across recent research. Analyst Commentary Recent research coverage has highlighted a generally constructive tone around Medpace, with several bullish analysts pointing to efficiency, exposure to biopharma clients, and margin profile as key parts of the equity story.

MEDP: Higher Margins And Buybacks Will Support Rich Market Expectations

Analysts have trimmed their average price target on Medpace Holdings by about $55 to $490.50 as revised models reflect updated revenue growth assumptions, a slightly different discount rate, higher expected profit margins, and a higher future P/E multiple, informed by a mix of recent upgrades and target changes across the Street. Analyst Commentary Recent research has produced a mix of upgrades and target cuts, with Street views clustering around how sustainable Medpace Holdings' growth, margins, and valuation may be after the latest earnings move.

Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target

Feb 13
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target

MEDP: Decelerating Healthcare Utilization Will Test Rich Multiple And 2026 Execution

Analysts have nudged their price target for Medpace Holdings slightly higher, to $660 from $655, citing updated Q4 healthcare utilization survey findings and modest tweaks to growth, margin and future P/E assumptions in their models. Analyst Commentary Recent research around Medpace focuses on how healthcare utilization trends could influence growth expectations, margins and the valuation investors are willing to pay.

MEDP: Biotech Recovery And Backlog Strength Will Challenge Rich Market Expectations

Narrative Update: Medpace Holdings Analyst Price Target Shift The updated analyst framework edges fair value for Medpace Holdings slightly higher to about $545.75 from roughly $541.92. This reflects modest tweaks to discount rate, growth, margin and P/E assumptions as analysts respond to a series of recent price target increases across the Street.

MEDP: Rich Multiple Will Depend On Unproven 2026 Execution

Analysts raised their fair value estimate for Medpace Holdings from about $305 to roughly $356 per share, citing higher assumed revenue growth, slightly improved profit margins, and a modestly higher future P/E multiple in line with recent Street price target increases. Analyst Commentary Recent Street research on Medpace highlights a mix of optimism on the long term setup and caution around how much upside is already reflected in the current share price.

MEDP: Biotech Funding Recovery And Backlog Trends Will Shape Future Prospects

Analysts have nudged their blended fair value estimate for Medpace Holdings slightly higher, to approximately $542 from $539, citing increased confidence in the durability of biotech recovery, a healthier pre-backlog pipeline, and signs that contract research trends have stabilized. Analyst Commentary Street research updates over the last several weeks reflect a generally constructive stance on Medpace, with multiple firms raising price targets while maintaining a range of ratings from Sell to Outperform.

MEDP: Biotech Funding Recovery And Book-To-Bill Trends Will Shape Future Outlook

Analysts have nudged their price target on Medpace Holdings modestly higher by about $2 per share to reflect increased confidence in a sustained recovery in biotech funding, healthier book to bill trends, and signs that contract research organization demand has likely stabilized. Analyst Commentary Recent Street research reflects a more constructive stance on Medpace, with several bullish analysts lifting price targets to account for stronger sector fundamentals and improved visibility into the company’s growth trajectory.

MEDP: Improving Biotech Pipeline And Book-To-Bill Trends Will Support Recovery Momentum

The analyst price target for Medpace Holdings has increased from $519 to $538. Analysts cite improving Biotech market confidence and stronger forward earnings projections as factors supporting this upward revision.

MEDP: Below-Normal Bookings In 2025 Will Pressure Revenue Expansion

Analysts have raised their price target for Medpace Holdings from $456 to approximately $519, citing higher growth estimates and renewed confidence in the CRO sector's recovery. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for Medpace, citing increased confidence in the recovery trajectory of the biotech sector and the broader contract research organization market.

Future Sector Demand Shifts Will Influence Risk And Reward Dynamics

Analysts have raised their fair value estimate for Medpace Holdings to $456 from $428 per share. This change reflects updated optimism based on recent price target adjustments and expectations for stabilization in contract research organization demand trends.

Tech-enabled Clinical Trials Will Balance Potential Risk And Reward

Analysts have raised Medpace Holdings’ fair value estimate modestly, from $423.64 to $428.00. Industry views reflect improved biotech funding and solid bookings, although some ongoing uncertainty in demand signals remains.

Tech-enabled Clinical Trials Will Balance Potential Risk And Reward

As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).

Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%

Aug 11
Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%

Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next

Jul 24
Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next

Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

Jul 01
Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

Is Medpace Holdings, Inc. (NASDAQ:MEDP) Trading At A 48% Discount?

Jun 12
Is Medpace Holdings, Inc. (NASDAQ:MEDP) Trading At A 48% Discount?

Investor Optimism Abounds Medpace Holdings, Inc. (NASDAQ:MEDP) But Growth Is Lacking

May 08
Investor Optimism Abounds Medpace Holdings, Inc. (NASDAQ:MEDP) But Growth Is Lacking

Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential

Feb 06

Medpace: Buy The Short-Term Pain For Long-Term Gains

Oct 26

Why Medpace Holdings Is A 'Better Mousetrap'

Oct 16
User avatar

Temporary Setbacks Poised For A Swift Recovery And Strong Future Revenue Growth

Elevated project cancellations pose only a temporary risk, with potential for quick revenue and net new business awards recovery.

Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity

Aug 20

Medpace: Clear Winner If China Blockade Succeeds

Jun 04

매출 및 비용 세부 내역

Medpace Holdings가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGS:MEDP 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Mar 262,6784601880
31 Dec 252,5304511980
30 Sep 252,3584331980
30 Jun 252,2324181990
31 Mar 252,1574161940
31 Dec 242,1094041800
30 Sep 242,0713661770
30 Jun 242,0303401690
31 Mar 241,9633121670
31 Dec 231,8862831610
30 Sep 231,7822731520
30 Jun 231,6732681460
31 Mar 231,5632571400
31 Dec 221,4602451310
30 Sep 221,3742271260
30 Jun 221,2862091180
31 Mar 221,2131991120
31 Dec 211,1421811080
30 Sep 211,0941821030
30 Jun 211,028175980
31 Mar 21955159930
31 Dec 20926145920
30 Sep 20896124910
30 Jun 20882107970
31 Mar 20891110990
31 Dec 19861100950
30 Sep 1982393950
30 Jun 1978688840
31 Mar 1974278810
31 Dec 1870573760
30 Sep 1861261720
30 Jun 1853152700
31 Mar 1845645640
31 Dec 1738639630
30 Sep 1738228630
30 Jun 1737923630
31 Mar 1737718630
31 Dec 1637113620
30 Sep 163615650
30 Jun 163480600
31 Mar 16332-5570
31 Dec 15320-9540

양질의 수익: MEDP는 고품질 수익을 보유하고 있습니다.

이익 마진 증가: MEDP의 현재 순 이익률 (17.2%)은 지난해 (19.3%)보다 낮습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: MEDP의 수익은 지난 5년 동안 연평균 21.6%로 크게 증가했습니다.

성장 가속화: 지난 1년간 MEDP 의 수익 증가율(10.6%)은 5년 평균(연간 21.6%)보다 낮습니다.

수익 대 산업: MEDP의 지난 1년 수익 증가율(10.6%)은 Life Sciences 업계의 2.5%를 상회했습니다.

자기자본이익률

높은 ROE: MEDP의 자본 수익률(76.9%)은 뛰어남으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/04/30 12:14
종가2026/04/29 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Medpace Holdings, Inc.는 20명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Eric ColdwellBaird
Luke SergottBarclays
Sean DodgeBMO Capital Markets Equity Research